ARTICLE INFO

Article Type

Original Research

Authors

Bakrani Balani   M. (1 )
Shahanipour   K. (* )
Mehrzad   V. (2 )






(* ) Biochemistry Department, Biological Sciences Faculty, Falavarjan Branch, Islamic Azad University, Isfahan, Iran
(1 ) Biochemistry Department, Biological Sciences Faculty, Fars Science & Research Branch, Islamic Azad University, Shiraz, Iran
(2 ) Internal Medicine Department, Medicine Faculty, Isfahan University of Medical Sciences, Isfahan, Iran

Correspondence

Address: No. 21, Parsian Building, Shahid Kouhanjani Alley, Khayam Street, Isfahan, Iran
Phone: +9831137653258
Fax: +9831137432601
shahanipur_k@yahoo.com

Article History

Received:   February  22, 2014
Accepted:   July 23, 2014
ePublished:   September 23, 2014

ABSTRACT

Aims Ovarian cancer is the most common lethal malignancy female reproduction system which is diagnosed in advanced stages in the majority of cases. The main purpose of this study was to compare serum level of β-hCG tumor markers, calcium, phosphorus and alkaline phosphatase enzyme activity in healthy subjects and patients with ovarian cancer and to investigate the possibility of using these factors as markers of ovarian cancer.
Materials & Methods This case-control study was carried out on people referring to Seyedoshohada Hospital in Isfahan and 44 women with ovarian cancer and 44 healthy women were studied from February 2012 to April 2012. β-hCG tumor marker was measured using ELISA method and serum calcium, phosphorus and alkaline phosphatase enzyme activity was measured by the photometric method. Independent T-test was used to compare studied indices between two groups.
Findings A significant difference was observed only between β-hCG mean of patient group (2.96±1.30 units per liter) and healthy group (2.27±1.17 units per liter) (p=0.014). The mean concentration of calcium, phosphorus and alkaline phosphatase activity were not significant between patients and healthy groups (p>0.05).
Conclusion β-hCG serum level in ovarian cancer patients undergoing chemotherapy or radiotherapy is more than healthy subjects. Also, serum level of calcium, phosphorus and alkaline phosphatase enzyme activity in ovarian cancer patients under therapy is not associated with the disease status.

Keywords: Ovary, β-hCG, Calcium, Phosphorus,

CITATION LINKS

[1]Nelson DL, Cox MM. Lehninger Principles of Biochemistry. 6th ed. New York, W.H. Freeman; 2012.
[2]Kyselova Z, Mechref Y, Kang P, Goetz JA, Dobrolecki LE, Sledge GW, et al. Breast cancer diagnosis and prognosis through quantitative measurements of serum glycan profiles. Clin Chem. 2008;54(7):1166-75.
[3]Vaseie M, Matin S, Alavi SMH. The evaluation of ovarian cancer symptoms and riskfactors in patients of Hazrat-e-Rasool and Shahid Akbarabadi Hospitals. J Army Uni Med Sci. 2010;8(2):112-7.
[4]Noori Daloii MR, Rashvand Z. Molecular genetics and gene therapy in ovarian cancer. Horizon Med Sci 2010;16(3):5-19. [Persian]
[5]Bast RC, Kufe DW, Pollock RE, Weichselbaum RR, Holland JF, Frei E. (Editors). Holland-Frei Cancer Medicine. 5th ed. Hamilton (ON): BC Decker; 2000.
[6]Fathi M, Mirshahi M, Garaati M. Valuation of monoclonal antibodies against HCG, on cancer cell. Tehran Uni Med J. 2011;69(9):523-8.
[7]Gawronska B, Leuschner C, Enright FM, Hansel W. Effects of a lytic peptide conjugated to beta HCG on ovarian cancer: studies in vitro and in vivo. Gynecol Oncol. 2002;85(1):45-52.
[8]Maleknia N. Harper's Biochemistry; Leninger and Devlin. Tehran: Mer; 2003.
[9]Mohammadian H. Biochemistry. Tehran: Tehran University Publications and Printing; 1999.
[10]Konishi I, Kuroda H, Mandai M. Review: Gonadotropins and development of ovarian cancer. Oncology. 1999; 57 (Suppl 2):45-8.
[11]Lenhard M, Tsvilina A, Schumacher L, Kupka M, Ditsch N, Mayr D, et al. Human chorionic gonadotropin and its relation to grade, stage and patient survival in ovarian cancer. BMC Cancer. 2012;12(1):2.
[12]Muller CY, Cole LA. The quagmire of hCG and hCG testing in gynecologic oncology. Gynecol Oncol. 2009;112(3):663-72.
[13]Djurdjevic S, Maksimovic M, Pantelic M, Golubovic A, Curcic A. Usefulness of beta hCG as tumor marker in the diagnosis and follow up of patients with ovarian cancer. Official J Balkan Union Oncol. 2011;16(4):715-21.
[14]Gilligan TD, Hayes DF, Seidenfeld J, Temin S. ASCO Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumors. J Oncol Pract. 2010;6(4)199-202.
[15]Ulbright TM. Germ cell tumors of the gonads: A selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues. Mod Pathol. 2005;18(Suppl 2):61-79.
[16]Skinner HG, Schwartz GG. Elevated serum calcium as a biological marker for ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2013;22(3):477.
[17]Toriola AT, Surcel HM, Calypse A, Grankvist K, Luostarinen T, Lukanova A, et al. Independent and joint effects of serum 25-hydroxyvitamin D and calcium on ovarian cancer risk: a prospective nested case-control study. Eur J Cancer. 2010;46(15):2799-805.
[18]Schwartz GG, Skinner HG. Prospective studies of total and ionized serum calcium in relation to incident and fatal ovarian cancer. Gynecol Oncol. 2013;129(1):169-72.
[19]Tholander B, Taube A, Lindgren A, Sjöberg O, Stendahl U, Kiviranta A, et al. Pretreatment serum levels of CA-125, carcinoembryonic antigen, tissue polypeptide antigen, and placental alkaline phosphatase, in patients with ovarian carcinoma, borderline tumors, or benign adnexal masses: relevance for differential diagnosis. Gynecol Oncol. 1990;39(1):16-25.
[20]Ben-Arie A, Hagay Z, Ben-Hur H, Open M, Dgani R. Elevated serum alkaline phosphatase may enable early diagnosis of ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 1999;86(1):69-71.